MedTrace Logo

Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）

NCT07278674 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-12-12

No results posted yet for this study

Summary

Evaluate the impact of maintenance therapy with eflornithine on event-free survival and overall survival in high-risk neuroblastoma (NB) children after immunotherapy, and assess its safety.

Conditions

  • High Risk Neuroblastoma

Interventions

DRUG

Oral administration of eflornithine for the prevention of high-risk neuroblastoma

This study is a single arm clinical observational study and does not involve control interventions

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Shanghai Children's Hospital

    lead OTHER

Principal Investigators

  • Jingbo Shao, PhD，chief physician · Shanghai Children's Hospital

  • Wen Su, PhD，associate chief physician · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-08
Primary Completion
2029-10-31
Completion
2029-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278674 on ClinicalTrials.gov